SCHEMBL1685398

SCHEMBL1685398

O=C1CN(c2ccccc2)C(=S)N1c1ccccc1

nearest known ligand 0.81

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.56
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
KDM4E B2RXH2 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MEN1 O00255 8/20 0.49
ALDH1A1 P00352 1/20 0.47
MGLL Q99685 1/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HPGD P15428 1/20 0.43
GRK5 P34947 1/20 0.43
TYRO3 Q06418 1/20 0.43
DYRK1B Q9Y463 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11072116 0.90 KMT2A (0.49) KMT2ANPC1RAB9AKDM4EGAA
SCHEMBL11065342 0.90 HTT (0.53) KMT2ANPC1RAB9AKDM4EGAA
SCHEMBL5955129 0.87 PLCG1 (0.55) KMT2ANPC1RAB9AKDM4EGAA
SCHEMBL11638136 0.87 NPC1 (0.56) KMT2ANPC1RAB9AGAAMEN1
SCHEMBL5955047 0.87 KMT2A (0.56) KMT2ANPC1RAB9AKDM4EGAA
SCHEMBL5955275 0.87 KMT2A (0.56) KMT2ANPC1RAB9AKDM4EGAA
SCHEMBL11071726 0.86 CTSG (0.51) KMT2ANPC1RAB9AKDM4EGAA
SCHEMBL6626141 0.84 MAPT (0.53) KMT2ANPC1RAB9AKDM4EGAA
SCHEMBL11147745 0.84 DUSP22 (0.47) KMT2ANPC1RAB9AKDM4EGAA
SCHEMBL23365830 0.83 DDB1 (0.47) KMT2ANPC1RAB9AKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3551182-A1 TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN TOPICAL INNOVATIONS B.V. (NL) 2019-10-16 EP claimed
WO-2018106108-A1 TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN KEPPEL HESSELING, Jan Marius (NL) 2018-06-14 WO claimed
US-20130005786-A1 THERAPEUTIC INVENTION KAPOOR RAJU (GB) 2013-01-03 US claimed
EP-3551182-B1 TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN TOPICAL INNOVATIONS B V (NL) 2025-03-19 EP disclosed
EP-3551166-B1 TOPICAL PHENYTOIN FOR USE IN THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN TOPICAL INNOVATIONS B V (NL) 2024-08-21 EP disclosed
US-11285099-B2 Topical phenytoin for use in the treatment of peripheral neuropathic pain TOPICAL INNOVATIONS B.V. (NL) 2022-03-29 US disclosed
US-11147799-B2 Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain Keppel Hesselink, Jan Marius (NL) 2021-10-19 US disclosed
US-20200276106-A1 TOPICAL PHENYTOIN FOR USE IN THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN TOPICAL INNOVATIONS B.V. (NL) 2020-09-03 US disclosed
US-20200069649-A1 TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -) ANALGESIC FOR THE TREATMENT OF CHRONIC PAIN TOPICAL INNOVATIONS B.V. (NL) 2020-03-05 US disclosed
EP-3551166-A1 TOPICAL PHENYTOIN FOR USE IN THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN TOPICAL INNOVATIONS B.V. (NL) 2019-10-16 EP disclosed
EP-3551182-A1 TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN TOPICAL INNOVATIONS B.V. (NL) 2019-10-16 EP disclosed
US-RE29168-E HEAT SENSITIVE, ANTIHALATION LAYER EASTMAN KODAK COMPANY (US) 1977-04-05 US disclosed
US-4007170-A SILVER HALIDE SENSITIZERS EASTMAN KODAK COMPANY (US) 1977-02-08 US disclosed
US-4002480-A CONTAINING A DINUCLEAR MEROCYANINE SENSITIZING DYE AND AN ANTIFOGGING AGENT FUJI PHOTO FILM CO., LTD. (JA) 1977-01-11 US disclosed
US-3976661-A SENSITIZERS, FILTERS EASTMAN KODAK COMPANY (US) 1976-08-24 US disclosed
US-3951666-A CYANINE AND MEROCYANINE DYES FUJI PHOTO FILM CO., LTD. (JA) 1976-04-20 US disclosed
US-3943142-A Dye intermediates and their preparation and use in the synthesis of methine dyes EASTMAN KODAK COMPANY (US) 1976-03-09 US disclosed
US-3936308-A Photographic emulsions containing methine dyes having a 1H-imidazo[4,5-b]pyrazine nucleus EASTMAN KODAK COMPANY (US) 1976-02-03 US disclosed
US-3935010-A IMIDAZOQUINOXALINE DESENSITIZER EASTMAN KODAK COMPANY (US) 1976-01-27 US disclosed
US-3932182-A An organic photoconductive composition comprising an organic photoconductive compound and a sensitizing compound having an active methylene group MITSUBISHI PAPER MILLS, LTD. (JA) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005786-A1 THERAPEUTIC INVENTION AQP4, PMP22, NHERF1 KMT2A 2062/4885NPC1 409/4885RAB9A 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.